ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies
→ The European Commission granted orphan drug designation to miRagen’s $MGEN MRG-106 for the treatment of cutaneous T-cell lymphoma (CTCL). “The European orphan drug designation for MRG-106 is another regulatory milestone which we believe further validates the medical need for novel therapies in the treatment of CTCL,” said miRagen president and CEO, William Marshall. It earned the FDA’s own orphan designation for treatment of mycosis fungoides—the most common subtype of CTCL—earlier this year. The Boulder, CO-based microRNA biotech found its way into the public markets last November, reverse merging with struggling Signal Genetics and gaining a $40 million round to finance clinical work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.